Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

115.70 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Horizon Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the... 
Via Benzinga
Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating
Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82. 
Via Investor's Business Daily
Horizon Therapeutics Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, Horizon Therapeutics (NASDAQ:HZNP) posted Q4 earnings of $173.18 million, an increase from Q3 of 46.97%. Sales dropped to $1.01 billion, a 2.22%... 
Via Benzinga
Horizon Therapeutics' Q4 Earnings Beat Expectation As Tepezza, Krystexxa Boost Sales
Horizon Therapeutics plc's (NASDAQ: HZNP) Q4 sales increased 36% Y/Y to $1.014 billion, beating the consensus of $995.87 million. The adjusted gross profit declined... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Horizon Therapeutics: Q4 Earnings Insights
Horizon Therapeutics (NASDAQ:HZNP) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Insider Buying Detected – Buy This Biotech Now
Biotech and pharmaceutical research are the hottest growing sectors in the global business market, brought into the public eye by the onset of the COVID-19 pandemic. 
Via Talk Markets
Horizon Therapeutics' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation
Horizon Therapeutics plc (NASDAQ: HZNP) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis... 
Via Benzinga
Death Cross Looms Over Horizon Therapeutics Investors
If history is any guide, there may be trouble ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "death cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
7 of the Top-Rated Pharmaceutical Stocks for Q1
As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. 
Via InvestorPlace
This Biotech CEO Is Trying To Cure His Son's Rare Disease
Few questions stump Tim Walbert. But the Horizon Therapeutics CEO is still working to answer one of them from his son. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
7 Drug Stocks to Buy Now While They’re Still on Sale
Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. 
Via InvestorPlace
Topics Supply Chain
Exposures COVID-19 Supply Chain
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
Stock Market Rally Keeps Running On Tesla, Nvidia, Fed Decision, Jobs Report: Weekly Review
But the Nasdaq is starting to look extended. 
Via Investor's Business Daily
Topics Bonds Economy Stocks
Exposures COVID-19 Debt Markets Interest Rates
Horizon Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro, during Q3, Horizon Therapeutics (NASDAQ:HZNP) earned $331.54 million, a 142.86% increase from the preceding quarter. Horizon Therapeutics also posted a... 
Via Benzinga
Horizon Pharma plc (HZNP) Q3 2021 Earnings Call Transcript
HZNP earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
CFO Retirement Plan Undoes Horizon Therapeutics Stock After Beat-And-Raise
Chief Financial Officer Paul Hoelscher will retire on May 16. 
Via Investor's Business Daily
Topics Retirement
Exposures Pension
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
Beam Therapeutics Stock Flashes Renewed Technical Strength
On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before. 
Via Investor's Business Daily
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Innoviva Stock In Buy Range; Joins Ranks Of Top-Performing Stocks With Strength Ratings Over 90
Innoviva stock is within a buy range after climbing above a 16.82 entry in a flat base. The proper buying range is up to 5% above the entry. 
Via Investor's Business Daily
Alkermes Stock Composite Rating Rises To Near-Perfect 96 As It Posts Erratic But Huge Sales Gains
The IBD SmartSelect Composite Rating for Alkermes rose from 94 to 96 Tuesday. 
Via Investor's Business Daily
Datadog, Netflix Lead Five Stocks Standing Tall In Market Correction
In a market correction, look for stocks with strong relative lines such as Netflix and Datadog. 
Via Investor's Business Daily
SEC Charges Former Goldman Sachs Officer For Insider Trading On 2 M&A Deals
The Securities and Exchange Commission has charged a former Goldman Sachs (NYSE: GS) compliance analyst with using confidential information to generate over $... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
9 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.